PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
Phosphatidylinositol 3-kinase (PI3K), protein kinase B (PKB/AKT) and mechanistic target of rapamycin (mTOR) (PAM) pathways play important roles in breast tumorigenesis and confer worse prognosis in breast cancer patients. The inhibitors targeting three key nodes of these pathways, PI3K, AKT and mTOR...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-08-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/11/16/2508 |
| _version_ | 1827617971729596416 |
|---|---|
| author | Kunrui Zhu Yanqi Wu Ping He Yu Fan Xiaorong Zhong Hong Zheng Ting Luo |
| author_facet | Kunrui Zhu Yanqi Wu Ping He Yu Fan Xiaorong Zhong Hong Zheng Ting Luo |
| author_sort | Kunrui Zhu |
| collection | DOAJ |
| description | Phosphatidylinositol 3-kinase (PI3K), protein kinase B (PKB/AKT) and mechanistic target of rapamycin (mTOR) (PAM) pathways play important roles in breast tumorigenesis and confer worse prognosis in breast cancer patients. The inhibitors targeting three key nodes of these pathways, PI3K, AKT and mTOR, are continuously developed. For breast cancer patients to truly benefit from PAM pathway inhibitors, it is necessary to clarify the frequency and mechanism of abnormal alterations in the PAM pathway in different breast cancer subtypes, and further explore reliable biomarkers to identify the appropriate population for precision therapy. Some PI3K and mTOR inhibitors have been approved by regulatory authorities for the treatment of specific breast cancer patient populations, and many new-generation PI3K/mTOR inhibitors and AKT isoform inhibitors have also been shown to have good prospects for cancer therapy. This review summarizes the changes in the PAM signaling pathway in different subtypes of breast cancer, and the latest research progress about the biomarkers and clinical application of PAM-targeted inhibitors. |
| first_indexed | 2024-03-09T09:58:57Z |
| format | Article |
| id | doaj.art-06b6cc2d35ac462aa16b32767bf1bc32 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-09T09:58:57Z |
| publishDate | 2022-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-06b6cc2d35ac462aa16b32767bf1bc322023-12-01T23:33:21ZengMDPI AGCells2073-44092022-08-011116250810.3390/cells11162508PI3K/AKT/mTOR-Targeted Therapy for Breast CancerKunrui Zhu0Yanqi Wu1Ping He2Yu Fan3Xiaorong Zhong4Hong Zheng5Ting Luo6Breast Disease Center, Cancer Center, West China Hospital, Sichuan University, Chengdu 610000, ChinaBreast Disease Center, Cancer Center, West China Hospital, Sichuan University, Chengdu 610000, ChinaBreast Disease Center, Cancer Center, West China Hospital, Sichuan University, Chengdu 610000, ChinaMulti-Omics Laboratory of Breast Diseases, State Key Laboratory of Biotherapy, National Collaborative, Innovation Center for Biotherapy, West China Hospital, Sichuan University, Chengdu 610000, ChinaBreast Disease Center, Cancer Center, West China Hospital, Sichuan University, Chengdu 610000, ChinaBreast Disease Center, Cancer Center, West China Hospital, Sichuan University, Chengdu 610000, ChinaBreast Disease Center, Cancer Center, West China Hospital, Sichuan University, Chengdu 610000, ChinaPhosphatidylinositol 3-kinase (PI3K), protein kinase B (PKB/AKT) and mechanistic target of rapamycin (mTOR) (PAM) pathways play important roles in breast tumorigenesis and confer worse prognosis in breast cancer patients. The inhibitors targeting three key nodes of these pathways, PI3K, AKT and mTOR, are continuously developed. For breast cancer patients to truly benefit from PAM pathway inhibitors, it is necessary to clarify the frequency and mechanism of abnormal alterations in the PAM pathway in different breast cancer subtypes, and further explore reliable biomarkers to identify the appropriate population for precision therapy. Some PI3K and mTOR inhibitors have been approved by regulatory authorities for the treatment of specific breast cancer patient populations, and many new-generation PI3K/mTOR inhibitors and AKT isoform inhibitors have also been shown to have good prospects for cancer therapy. This review summarizes the changes in the PAM signaling pathway in different subtypes of breast cancer, and the latest research progress about the biomarkers and clinical application of PAM-targeted inhibitors.https://www.mdpi.com/2073-4409/11/16/2508AKTbiomarkerbreast cancercancer therapymTORPI3K |
| spellingShingle | Kunrui Zhu Yanqi Wu Ping He Yu Fan Xiaorong Zhong Hong Zheng Ting Luo PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer Cells AKT biomarker breast cancer cancer therapy mTOR PI3K |
| title | PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer |
| title_full | PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer |
| title_fullStr | PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer |
| title_full_unstemmed | PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer |
| title_short | PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer |
| title_sort | pi3k akt mtor targeted therapy for breast cancer |
| topic | AKT biomarker breast cancer cancer therapy mTOR PI3K |
| url | https://www.mdpi.com/2073-4409/11/16/2508 |
| work_keys_str_mv | AT kunruizhu pi3kaktmtortargetedtherapyforbreastcancer AT yanqiwu pi3kaktmtortargetedtherapyforbreastcancer AT pinghe pi3kaktmtortargetedtherapyforbreastcancer AT yufan pi3kaktmtortargetedtherapyforbreastcancer AT xiaorongzhong pi3kaktmtortargetedtherapyforbreastcancer AT hongzheng pi3kaktmtortargetedtherapyforbreastcancer AT tingluo pi3kaktmtortargetedtherapyforbreastcancer |